Can I read Jamadermatology Paller 2022 Oi 220013 1659644541.56496 on EtoBox?

Jamadermatology Paller 2022 Oi 220013 1659644541.56496 by rosalia is a document available to read on EtoBox.

What is Jamadermatology Paller 2022 Oi 220013 1659644541.56496 about?

The IXORA-PEDS trial evaluated the long-term efficacy and safety of ixekizumab in pediatric patients with moderate to severe plaque psoriasis over 108 weeks. Results showed significant improvements in psoriasis severity scores, with high rates of skin clearance and no new safety concerns reported. The findings indicate that ixekizumab is a safe and effective treatment option for this population, consistent with previously established safety profiles.

Author

rosalia

Language

EN